Press release BoxID: 626889 (Ypsomed AG)
  • Ypsomed AG
  • Brunnmattstrasse 6
  • 3401 Burgdorf
  • Contact person
  • Benjamin Overney
  • +41 (34) 4244159

Ypsomed further expands its partnership in China

(PresseBox) (Burgdorf, ) Tonghua Dongbao Pharmaceutical Co., Ltd. and Ypsomed are announcing a new insulin pen system for the Chinese market. The Sulin Pen is based on the YpsoPen® technology platform, an inexpensive reusable pen. The value Sulin Pen perfectly complements the existing premium Gansulin Pen, which is based on Ypsomed's ServoPen® platform.

Tonghua Dongbao Pharmaceutical Co., Ltd. and Ypsomed have operated in partnership for over 10 years years. CEO and chairman of the board Willy Michel is delighted that, with the Sulin Pen, Tonghua Dongbao Pharmaceutical Co., Ltd. is now sourcing its fourth pen system from Ypsomed: "The success of the insulin pens in the People's Republic of China reinforced the decision of Mr Yikui Li, the President of Tonghua Dongbao Pharmaceutical Co., Ltd., to continue and extend the well-established partnership with Ypsomed." The attractively priced Sulin Pen is a reusable insulin pen that meets all the requirements of a modern injection system and is the ideal extension to the existing Gansulin Pen. While the Gansulin Pen continues to be the optimal choice for premium customers in affluent towns and cities, the Sulin Pen will be used to open up rural regions. Simon Michel, Head of Marketing and Sales in the Ypsomed Group, is convinced that: "As a local insulin provider, Tonghua Dongbao Pharmaceutical Co., Ltd. specifically needs the Sulin Pen to increase its market share in China still further".

The Dongbao Enterprise Group ( was founded in 1985 and as a result of significant investments in research and development has grown to become one of the leading pharmaceutical companies in China with 20 subsidiaries. As a manufacturer of active pharmaceutical ingredients (APIs), the company holds numerous patents and supplies millions of people in China and Asia with drugs, particularly human insulin. Current estimates put the figure for diabetes sufferers in China at more than 90 million.

Ypsomed AG

The Ypsomed Group is a leading, independent Swiss developer and manufacturer of injection systems for selfmedication and a renowned diabetes specialist with over 25 years of experience. Founded in 2003 from the wellknown company Disetronic, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife(TM) Diabetescare and YDS(TM) Ypsomed Delivery Systems in retailing and in business-to-business trading. Under the brand name mylife(TM) Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS(TM) reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements; contract development and manufacturing; as well as the assembly of injection systems with medications, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed group has around 1,000 employees.